Small bowel adenocarcinoma (SBA) three years after colonic adenocarcinoma in an elderly patient: Case report in a National Institute of Health and Aging (INRCA) and review of the literature  by Coco, Danilo et al.
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INTRODUCTION:  Adenocarcinoma  of the  small  intestine  is a  rare  malignancy  (the  annual  incidence  in the
USA  is approximately  3.9  cases  per  million  persons  with  median  age  between  60  and  70  years)  with
limited  data  available  to  guide  therapeutic  decisions.  Nonspeciﬁc  signs  and  symptoms  associated  with
difﬁculty in performing  small  bowel  examination  is  the  cause  of delayed  diagnosis  made  between  6  and
9  months  after appearance  of  symptoms  with  the  majority  of patients  presenting  with  late  stage  disease
and  either  lymph  node  involvement  or distant  metastatic  disease.
PRESENTATION  OF  CASE:  An 87-year-old  man  treated  3 years  previously  for  colonic  adenocarcinoma  with
left colectomy,  was  brought  to  our  attention  with  a  4.5  cm × 3.5  cm mass  in  the  proximal  jejunum  asso-
ciated  with  another  abdominal  wall  enhancing  mass  of 5 cm in diameter  in the  rectus  muscle.  Diagnosis
on  gross  examination  after surgical  resection  was  adenocarcinoma  stage  III (T4N1M0)  with  involvement
of  lymph  nodes.
DISCUSSION:  According  to an analysis  of  the  Surveillance,  Epidemiology  and  End  Results  (SEER) database,
patients  who  develop  either  a small  or large  intestine  adenocarcinoma  are at increased  risk  for  a second
cancer  at both  intestinal  sites.  The  role  of  adjuvant  therapy  in  patients  who  undergo  curative  resection  is
unclear.  Recent  retrospective  and  prospective  studies  have  helped  to clarify  the  optimal  chemotherapy
approach  for advanced  small  bowel  adenocarcinoma.
CONCLUSION:  With  our  work,  we  present  our  personal  case  of  metachronous  primary  carcinoma  of  small
bowel following  resected  colorectal  carcinoma  and review  the literature.
.  Pub
he  CC© 2014  The  Authors
access  article  under  t
. Introduction
The annual incidence of SBA (Small Bowel Adenocarcinoma) in
he USA is approximately 3.9 cases per million persons with median
ge between 60 and 70 years.1,2 According to 1992–2006 data from
he Surveillance, Epidemiology and End Results (SEER) the aver-
ge annual age-adjusted incidence rates per 100,000 population of
arcinomas of the small intestine is 1.45 and 1.00 for males and
emales respectively. Rates for blacks is more than twice those of
hites (1.29 vs. 0.63).2,3
Despite the small intestine representing approximately 70–80%
f the length and 90% of the surface area of the alimentary tract,
he incidence of adenocarcinoma of the small intestine is approxi-
ately forty- to ﬁfty fold less common than colorectal cancer and
he reason is largely unknown but has been hypothesized to be
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related to several mechanisms such as the much quicker transit
time of food in the small intestine than in the large intestine with
the shorter time of exposure of its mucosa to carcinogens or the
lower bacterial load of small intestine, which decreases concentra-
tion of potential carcinogens from bile acid breakdown and other
factors (Overman, 2009).2,4
Adenocarcinoma is the most common malignancy particularly
in the proximal small intestine, as reported by Overman, accord-
ing to a review of 25,053 patients from the National Cancer Data
Base, involving the following sites: 56% duodenum, 16% jejunum,
13% ileum, and 15% not identiﬁed. The cause of this propensity
for adenocarcinomas to occur in the duodenum rather than in the
jejunum/ileum is unknown. Lowenfels and others, have ascribed
this difference in risk to the higher concentration of bile and its
metabolites in the duodenum, secondary to the presence of the
ampulla of Vater.1–5Most SBAs arise from preexisting adenomas with one third of
solitary small bowel adenoma transforming into invasive carci-
noma. Nonspeciﬁc signs and symptoms associated with difﬁculty
in performing small bowel examination is the cause of a delayed
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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of patients with this tumor are not well known.7,8
All those patients, in earlier clinical visits, showed predisposing
conditions such as HNPCC (Hereditary Non Polyposis ColorectalCASE  REPORT
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iagnosis made between 6 and 9 months after appearance of symp-
oms.
Patients treated for a colorectal cancer have an increased risk of
eveloping a second primary malignant disease (30–40%, Enblad
t al., 1990).6 With our work, we want to present our personal
ase of metachronous primary carcinoma of small bowel following
esected colorectal carcinoma and review the literature.
. Clinical case
An 87-year-old man  was brought to our attention with a sev-
ral month history of nausea, abdominal bloating, early satiety and
eight loss. He had a prior history of hypertension, diabetes mel-
itus, peptic ulcer disease and left colectomy for primary sigmoid
denocarcinoma 3 years earlier (T4N0M0) without adjuvant ther-
py due to his advanced age.
His hemoglobin measured 12 g/dL, serum ferritin 16.2 g/mL,
ron 41 g/dL, and total iron binding capacity 370 g/dL. His iron
aturation level was 11.1%, consistent with iron deﬁciency anemia.
he remaining blood tests, including hepatic and renal function,
ere normal. The patient underwent a complete workup for iron
eﬁciency anemia.
An initial upper endoscopy was normal. Duodenal and gastric
ntrum biopsies were negative for Helicobacter pylori. Colono-
copic evaluation showed only diverticular disease. Small bowel
ollow-through (SBFT) examination was normal. The patient was
reated with proton pump inhibitors, antiemetics, and iron supple-
ents, then was lost to follow-up for approximately 10 months.
Subsequently, he was readmitted with persisting nausea and
bdominal bloating with new-onset diarrhea, chest pain, and short-
ess of breath. Physical examination demonstrated gastrointestinal
istension associated with a 5 cm mass in rectus muscle, bilat-
ral pulmonary rales and tachycardia. His hemoglobin measured
 g/dL with iron deﬁciency. At this time an abdominal computed
omography (CT) scan was required and it showed a 4.5 cm × 3.5 cm
ass in the proximal jejunum with a “target jejunum image” like
n intestinal invagination associated with another abdominal wall
nhancing mass 5 cm in diameter in the rectus muscle (Fig. 1). Cys-
ic areas were found in the left iliac zone. The chest and the pancreas
n CT imaging appeared normal. Serum Carcino Embryonal Antigen
CEA) level was also normal.
At this point, the patient underwent an exploratory laparotomy
ith resection of the mass, which was located approximately 60 cm
istal to the ligament of Treitz, using an intestinal resection and side
o side hand-sewn anastomosis, resection of rectus muscle mass
nd pelvic lymphadenectomy.
On gross examination, the resected specimen showed a well-
ircumscribed exophytic mass with central ulceration, measuring
 cm in size with clear margins and involving the mesentery (Fig. 2).
Diagnosis was  jejunal adenocarcinoma stage III (T4N1M0) with
nvolvement of mesenteric and pelvic lymph nodes, the mass of rec-
us muscle was deﬁned as metastasis of sigmoid adenocarcinoma.
Due to age and his Karnofsky stage, no adjuvant chemotherapy
r radiation was administered by the oncologists. The patient’s GI
ymptoms resolved following surgery.
The total time from the onset of symptoms to the diagnosis of
he small-bowel adenocarcinoma was 12 months. After resection
he patient continued to do well with normal hematocrit levels
t 6 months follow-up, then he suffered new abdominal pain in
ssociation with anemia, fatigue and weight loss with a recurrence
f iliac mass in the lower right quadrant. He died after one year
f follow-up for cardiovascular and pulmonary complications (24
onths from the onset of symptoms).Fig. 1. Abdominal computed tomography. (A) rectus muscle mass and (B) proximal
jejunum mass.
3. Discussion
SBA is a rare tumor and to our knowledge few published studies
in the literature to date have addressed it adequately, for these
reasons clinical characteristics, treatment modalities and prognosisFig. 2. Macroscopic aspect of the mass.
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Table  1
TNM staging for adenocarcinoma of the small intestine Overman.2
Primary tumor (T)
TX Primary tumor cannot be assessed
T0  No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor invades lamina propria or submucosa
T2  Tumor invades muscularis propria
T3  Tumor invades through muscularis propria into the subserosa or into
the nonperitonealized perimuscular tissue (mesentery or
retroperitoneum) with extension 2 cm or lessa
T4 Tumor perforates the visceral peritoneum or directly invades other
organs or structures (includes other loops of small intestine,
mesentery, or retroperitoneum more than 2 cm,  and abdominal wall
by  way of serosa; for duodenum only, invasion of pancreas)
Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage grouping
Stage 0 Tis N0 M0
Stage I T1 N0 M0
T2  N0 M0
Stage II T3 N0 M0
T4  N0 M0
Stage III Any T N1 M1
Stage IV AnyT AnyN AnyM1
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adapted from AJCC Cancer Staging Manual, Sixth Edition.
a The peritonealized perimuscular tissue is for the jejunum and ileum, part of the m
ancer), FAP (Familial Adenomatous Polyposis), inﬂammatory
owel disease (IBD), or celiac disease.
In particular, Crohn’s disease is a recognized risk factor for
ancer of the small intestine, as reported in a meta-analysis that
eported a relative risk of 33.2 (95% CI: 15.9–60.9) while it is unclear
or patients with ulcerative colitis.3,9–11
Celiac disease’ prevalence is nearly 1% of the general population
nd the relative risk of adenocarcinoma in these patients is reported
etween 60 and 80.3,10
It is suggested that adenocarcinoma of the small bowel follows
he same sequence of colon cancer. In a retrospective analysis of
92 villous adenomas of the duodenum, the incidence of malignant
hanges at the time of presentation was 42%. Most of the adeno-
as  in the small bowel occur in the duodenum. Villous histology,
ncreasing size and a higher grade of dysplasia of the adenoma
ncrease the risk of neoplastic transformation from adenoma to
arcinoma.3,10
In fact, 3–5% of patients with FAP, where the prevalence of duo-
enal adenomatosis is 50–90%, develop duodenal cancer, while a
eta-analysis of 210 patients with PJS (Peutz–Jeghers Syndrome)
resented a statistically signiﬁcant increase in relative risk for can-
er of small bowel (RR = 520), stomach (RR = 213), colon (RR = 84),
sophagus (RR = 57), pancreas (RR = 132), lung (RR = 17), breast
RR = 15.2), uterus (RR = 16.0) and ovary (RR = 27) respectively. The
elative risk of small bowel cancer in patients with HNPCC has
een estimated to be more than 100 compared with the general
opulation, with a lifetime risk of 1–7%.3,10,11
Moreover, various studies have shown that the risk of SBA
ollowing primary colorectal cancer was elevated (30% and 40%
espectively for colon and rectum cancer)6; also, in those diagnosed
ith primary SBA, there was a 4–5-fold risk of developing colorec-al cancer. These studies suggest etiological similarities between
ancers of the small intestine and colorectal cancers but, to date,
otential common carcinogenic agents have not been elucidated in
nalytic epidemiological studies.3–11ery; and for duodenum in areas where serosa is lacking, part of the retroperitoneum.
The most commonly reported symptoms of SBA are abdominal
pain, nausea/vomiting, weight loss, and gastrointestinal bleeding
and they are identiﬁed with barium follow-through examination
in only 33% of cases, whereas 90% of them could be identiﬁed with
small bowel enema. Overall sensitivity, speciﬁcity, and accuracy of
multidetector row helical computed tomography (CT) enteroclysis
for small bowel disease are 100%, 95%, and 97%, respectively, and
86%, 98%, and 97%, respectively, for magnetic resonance (MR) ente-
roclysis, while video capsule enteroscopy (VCE) was introduced in
2001 and its diagnostic yield is approximately 50% to 60% for small
bowel lesions.2–9,12–14
Staging for small bowel adenocarcinoma is performed accord-
ing to the American Joint Committee on Cancer (AJCC) guidelines,
which is based on the TNM staging system (Table 1).2
In a review from the National Cancer Data Base, from 1985 to
1995 5-year disease speciﬁc survival by stage was 65% for stage I,
48% for stage II, 35% for stage III, and 4% for stage IV.2,15–17
The mainstay treatment of SBA remains surgery, in particular
laparotomy for resection of the involved segment (10 cm distant
from proximal and distal margin of the tumor), the mesentery
and the lymphatics up to the superior mesenteric vessels. Mor-
bidity and mortality are respectively between 13% and 44% and
between 3% and12%. The 5 year overall survival varies between 9%
and 50%.2–9,16–18
Only a limited number of single-institution retrospective stud-
ies have evaluated the role of adjuvant chemotherapy although the
beneﬁt has not been clearly demonstrated. Capecitabine or infu-
sional 5-FU combined with oxaliplatin appears to be one of the
most active combinations and should be considered for front-line
treatment of patients with this cancer (median survival in the range
of 14–20 months).2–18–20Different studies have tried to determine patterns of treatment
and factors that can inﬂuence survival of patients with SBA. Howe
(1999) reported, according to the National Cancer Database (NCDB)
information on 4995 patients with SBA, that patient age was the
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able  2
oor prognostic factors from multivariate analyses Overman.2
Study Time period No. Pts Multivariate factors
Small intestine
Bilimoria 1985–2005 25,053 Age > 55 years
Male
Black ethnicity
Duodenal or ileal location
T4 tumor stage
Lymph node involvement
Metastatic disease
Poor differentiation
Positive margins
Howe 1985–1995 4995 Regional or distant disease
Age > 75 years
Duodenal location
Poor differentiation
Dabaja 1978–1998 217 Lymph node ratio > 75%
Curative resection
Wu 1983–2003 80 TNM stage III/IV
Curative resection
Lymph node involvement
Agrawal 1971–2005 64 T4 tumor stage
Non-curative resection
Metastatic disease
Duodenum
Rose 1983–1994 79 Metastatic disease
Non-curative resection
Bakaeen 1976–1996 68 TNM stage III/IV
Positive margins
Weight loss
Lymph node involvement
nly factor related to Overall Survival (OS). The relative risk of death
as 1.8 times higher for patients age > 75 years.21–23
In a French study of 100 patients with SBA, Veyrieres (1997)
eported that curative resection resulted in a 5-year survival rate
f 63% without lymph node involvement and 52% with lymph
ode involvement. He also reported that the survival rate was 57%
n cases without serosal involvement, 53% in those with serosal
nvolvement, 56% when the tumor was well or moderately differ-
ntiated compared with 40% when it was undifferentiated.1–3,23
In a review of 77 patients with SBA, undifferentiated histologic
rade was associated with a trend toward shorter OS but this did not
each statistical signiﬁcance (P = 0.4). Thirty-ﬁve percent of patients
resented with advanced stage disease (Stage IV), possibly as a
esult of delayed diagnosis. In the same study, Maglinte found an
verage delay in diagnosis of 8.2 months attributable to the physi-
ian’s failure to order the appropriate tests and a delay of 12 months
due to the radiologist’s failure to make the diagnosis. Duodenal
adenocarcinoma was  associated with a shorter median OS com-
pared with patients with tumors located in the jejunum or ileum
(18 months vs. 26 months), a ﬁnding that is in accordance with pre-
viously published studies. These patients were signiﬁcantly older
(P > 0.001) and tended to present with late stage disease (69% with
Stage III disease) compared with patients with distally located ade-
nocarcinoma (jejunum and ileum), which may  explain the shorter
survival.1,2,5–8,24
To date, there are no clear associations between tumor mark-
ers and small intestine adenocarcinoma. Some patients with small
intestine adenocarcinoma have been found to have elevated serum
CA19-9 or CEA concentrations. Recurrences were observed in
40–70% of patients who  underwent curative resection, with most
recurrences at distant sites.
The various factors that have been associated with poor prog-
nosis in multivariate analyses from the literature are reported
in Table 2, in particular they are late disease stage, lymph node
involvement, poor histologic differentiation, elderly age, duodenal
primary, and positive margins.2,17–24
To summarize, early diagnostic workup of patients with vague
abdominal symptoms and complete surgical resection remain the
most signiﬁcant variables in improving outcome of patients with
small bowel adenocarcinoma.
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Key learning points
• Curative resection is currently the only factor that can prolong patient survival. Consequently, early and accurate
diagnosis is crucial to improve patient outcomes.
• Physician’s suspicion and awareness of SBA (Small bowel adenocarcinoma) is crucial to make appropriate diagnostic
investigation for earlier detection and increasing resecability of SBA.
• Due to the rarity of these tumors, multi institutional cooperation is essential for the success of these studies.eferences
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